📢 @Vivet Therapeutics is heading west for The Liver Meeting in sunny ☀ San Diego, California! ⛱
Listen in as #Vivet’s Co-founder & Chief Scientific Officer, Dr @Gloria Gonzalez-Aseguinolaza presents 🎤 key findings on #VTX-806, our gene therapy program for Cerebrotendinous Xanthomatosis (#CTX) at The Liver Meeting (#TLM) presented by the @American Association for the Study of Liver Diseases (AASLD) on Monday 18 November. Read the full press release here👉[bitly link to PR on Vivet website]
Details of the presentations are highlighted below:
📢 Oral Presentation Title: Liver-directed gene therapy normalizes toxic bile acid metabolite levels in the blood and brain of mice with cerebrotendinous xanthomatosis
📅 Date: Monday 18 November 🕘 Time: 08:00-9:30 PST
📜 Session: From Bench to Bedside: State of the Art Diagnostics and Therapeutics in Genetic and Metabolic Liver Disease
🔢 Presentation Number: 0230
📌Poster Presentation Title: Long-term metabolic, phenotypic, and neuropathological characterization of the Cyp27a1-/- mouse model of cerebrotendinous xanthomatosis
📅 Date: Monday 18 November 🕘 Time: 08:00-17:00 PST
📜 Session: Metabolic and Genetic Disease
🔢 Poster Number: 4476
📍 Location: Poster Hall C
Don’t miss the opportunity to connect 🤝with Gloria to learn more about Vivet’s novel and long-lasting gene therapies for rare inherited metabolic conditions.
Celebrating its 75th year, the #AASLD #TheLiverMeeting is renowned for cutting-edge science and is the place to be to discover the latest advancements and innovations in #hepatology and engage with industry experts driving change.
